Tetsuya Fujii

MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors

W. Lam, J. Minna, J. Soh, 2009, International journal of cancer.

ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer.

J. Soh, S. Toyooka, K. Kiura, 2008, Lung cancer.

Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells.

H. Fujiwara, S. Herrmann, T. Hamaoka, 1995, International immunology.

MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors

W. Lam, J. Minna, J. Soh, 2009, International journal of cancer.